8-K 1 rgbp20150224form8k.htm FORM 8-K Form 8-K - Filed by SimpleSEC



Washington, D.C.  20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): February 18, 2015



(Exact name of small business issuer as specified in its charter)


Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

Commission File No. 333-191725


4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)


(619) 702 1404

(Issuer’s telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events

On February 18, 2015 the Board of Directors of Regen Biopharma, Inc.(“Regen”) declared a dividend to common shareholders of record as of March 10, 2015 (“Record Date”) to be paid to common shareholders on or about March 20, 2015, such dividend to be payable in shares of Regen’s authorized but unissued Series A Preferred Stock and to consist of one share of Series A Preferred Stock for every ten common shares of Regen Common Stock owned as of the Record Date.




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Regen Biopharma, Inc.
Dated: February 24, 2015 By: /s/ David Koos
  David Koos
  Chief Executive Officer